Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, of Yale University, New Haven, Connecticut, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a distinguished award at the 17th World Conference on Lung Cancer in Vienna, Austria. Dr. Herbst accepted the Paul A. Bunn Jr. Scientific Award in honor of his scientific contributions to thoracic cancer research.
Dr. Herbst is Ensign Professor of Medicine; Professor of Pharmacology; Chief of Medical Oncology; Director of the Thoracic Oncology Research Program; and Associate Director for Translational Research at the Yale Cancer Center and Yale School of Medicine.
Dr. Herbst’s efforts over the past several decades have included bringing targeted agents to clinical trials— and ultimately U.S. Food and Drug Administration approval—and leading clinical trials to said agents in advanced-stage cancers.
Fred R. Hirsch, MD, PhD,
“Dr. Herbst has committed his entire career to advancements in lung cancer research,” said Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine and Chief Executive Officer of the International Association for the Study of Lung Cancer. “The IASLC is very proud to honor Dr. Herbst for his very significant contributions, which already have helped many lung cancer patients. He has made a tremendous impact across the globe, and we are confident his quality work will continue to be crucial in the fight against lung cancer.”
Dr. Herbst earned his MD from Cornell University Medical College and his PhD in molecular cell biology from Rockefeller University in New York. Dr. Herbst also holds a master’s degree in clinical translational research from Harvard University. ■
